RxDoctor Payments Data

Kevin Young, MD

Psychiatry · Crowley, LANPI 1356312912

Payments from drug & device makers

$1,678in general payments, 2019–2025

Across 82 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$335
  • Neurocrine Biosciences, Inc.$313
  • Johnson & Johnson$206
  • Alkermes, Inc.$201
  • AbbVie$179
  • Axsome Therapeutics, Inc.$143
  • plus $302 from 6 others

What the payments were for

  • Food & beverage$1,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 70th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,014
Medicare patients
34
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate47$397,902
Invega SustennaPaliperidone Palmitate31$81,201
VraylarCariprazine Hcl41$58,504
Abilify MaintenaAripiprazole22$56,749
Oxcarbazepine139$5,326
Duloxetine Hcl227$3,165
Trazodone Hcl262$2,418
Aripiprazole96$2,119
Ziprasidone Hcl29$1,925
Bupropion XlBupropion Hcl133$1,659
Quetiapine Fumarate163$1,429
Mirtazapine172$1,315
Buspirone Hcl69$1,015
Hydroxyzine Pamoate69$591
Escitalopram Oxalate74$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$313$397,90247 claims
Johnson & JohnsonInvega Sustenna$206$81,20131 claims
AbbVieVraylar$179$58,50441 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$91$56,74922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Crowley

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →